Hollings Cancer Center at the University of South Carolina
Charleston, South Carolina, is proudly home to University of South Carolina’s Hollings Cancer Center. Known worldwide for its deep contributions to cancer research and treatment, the center opened its doors as a cancer center in 1993 and is now one of the most prominent educational centers associated with cancer.
Training over 2,350 medical professional annually, the center has grown to harbor six separate colleges. Over 100 medical specialists lead the institutions clinical research, treatment, and education advancing the treatment options for those afflicted by cancer. The phenomenal success of the center has attracted over 75,000 outpatients in 2010 as well as over $30 million in research funds provided by some of the most reputable cancer institutions in the United States.
One of the centers leading programs, the Thoracic Oncology Program, is comprised of a multidisciplinary team of specialists that focus in areas ranging from tracheal cancers to thymomas.
With an array of both traditional and innovative treatment options, patients receive well rounded opinions from our uniquely qualified team. This allows for patients to receive their all their medical needs in one, convenient location. Many treatments are completed in combination with each other to increase their effectiveness.
Some treatments provided include:
-
Intensive surgery, involved in the removal of tumors, often in combination with chemotherapy
-
Brachytherapy, a new form of radioactive procedure that saves patients’ healthy tissues while targeting cancerous ones
-
Tomotherapy, or the interactive use of radiation with CT scanning technology
With the assistance of a stellar clinical research team, MUSC has established itself a leader in medical academia. The National Cancer Institute has approved of five research programs lead by nearly two dozen departments across numerous accredited educational institutions and colleges. Some of the research programs include the Cancer Immunology Program and the Developmental Cancer Therapeutics Program.